HomeCompareEGFEY vs PFE

EGFEY vs PFE: Dividend Comparison 2026

EGFEY yields 1.49% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EGFEY wins by $19.28M in total portfolio value
10 years
EGFEY
EGFEY
● Live price
1.49%
Share price
$2.01
Annual div
$0.03
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$19.33M
Annual income
$17,125,628.16
Full EGFEY calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — EGFEY vs PFE

📍 EGFEY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodEGFEYPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, EGFEY + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
EGFEY pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

EGFEY
Annual income on $10K today (after 15% tax)
$126.87/yr
After 10yr DRIP, annual income (after tax)
$14,556,783.94/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, EGFEY beats the other by $14,534,464.03/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of EGFEY + PFE for your $10,000?

EGFEY: 50%PFE: 50%
100% PFE50/50100% EGFEY
Portfolio after 10yr
$9.69M
Annual income
$8,575,943.44/yr
Blended yield
88.51%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

EGFEY
Analyst Ratings
3
Buy
Consensus: Buy
Altman Z
0.2
Piotroski
4/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

EGFEY buys
0
PFE buys
0
No recent congressional trades found for EGFEY or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricEGFEYPFE
Forward yield1.49%6.13%
Annual dividend / share$0.03$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%13.2%
Portfolio after 10y$19.33M$49.6K
Annual income after 10y$17,125,628.16$26,258.71
Total dividends collected$19.13M$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyHold

Year-by-year: EGFEY vs PFE ($10,000, DRIP)

YearEGFEY PortfolioEGFEY Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$10,999$298.51$9,153$693.39+$1.8KEGFEY
2$12,382$613.67$8,593$849.25+$3.8KEGFEY
3$14,540$1,291.34$8,336$1,066.78+$6.2KEGFEY
4$18,392$2,834.41$8,437$1,384.80+$10.0KEGFEY
5$26,381$6,701.59$9,013$1,875.40+$17.4KEGFEY
6$46,196$17,967.38$10,306$2,680.72+$35.9KEGFEY
7$108,237$58,807.46$12,820$4,101.38+$95.4KEGFEY
8$373,358$257,545.03$17,673$6,826.70+$355.7KEGFEY
9$2,060,039$1,660,545.24$27,543$12,591.86+$2.03MEGFEY
10$19,329,869$17,125,628.16$49,560$26,258.71+$19.28MEGFEY

EGFEY vs PFE: Complete Analysis 2026

EGFEYStock

Eurobank Ergasias Services and Holdings S.A., together with its subsidiaries, provides retail banking, corporate and private banking, asset management, treasury, capital markets, and other services primarily in Greece, and Central and Southeastern Europe. It operates through Retail, Corporate, Global Markets & Asset Management, International, Investment Property, and Other segments. The company offers current accounts, savings, deposits and investment savings products, credit and debit cards, small business banking, mortgages, overdrafts, loans and other credit facilities, foreign currency and derivative products, custody and clearing services, and cash management and trade services, as well as corporate finance, and merger and acquisitions advice services. It also provides financial instruments trading services to institutional investors, as well as specialized financial advice and intermediation. In addition, the company offers mutual fund products, and institutional asset management and equity brokerage services. Further, it is involved in the investment property activities related to a portfolio of commercial real estate assets. Additionally, the company engages in the property management and other investing activities; and provision of private banking services for medium and high net worth individuals. In addition, the company offers business-to-business e-commerce, accounting, tax, leasing, factoring, loans and credits claim management, credit card and fund management, real estate, and other services. Further, it engages in the informatics data processing activities. As of March 31, 2022, the company had a network of 647 branches and business/private banking centers. Eurobank Ergasias Services and Holdings S.A. was founded in 1990 and is based in Athens, Greece.

Full EGFEY Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this EGFEY vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

EGFEY vs SCHDEGFEY vs JEPIEGFEY vs OEGFEY vs KOEGFEY vs MAINEGFEY vs JNJEGFEY vs MRKEGFEY vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.